Aptuit bolsters its preclinical services with Exquiron acquisition
The deal – financials of which have not been revealed – sees Aptuit bolster its early phase offerings by incorporating Exquiron’s assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization capabilities.
“The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery,” Aptuit CEO Jonathan Goldman said.
“In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination.”
He added customers were set to benefit from improved probability of candidate nomination, leading to reductions in time and cost.
“Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities”.
The acquisition comes two months after Aptuit boosted its preclinical services through a partnership with Icagen, adding Icagen’s collection of ion channel cell lines and its proprietary high throughput analysis XRpro platform to its service offering.
